Bedside markers of coronary artery patency and short-term prognosis of patients with acute myocardial infarction and thrombolysis.
BACKGROUND
In this study we have evaluated the prognostic power of noninvasive markers of coronary artery reperfusion in patients with acute myocardial infarction who were treated with intravenous streptokinase.


METHODS
In 967 consecutive patients with acute myocardial infarction who were treated within 6 hours of symptoms, we analyzed the prognostic power of resolution of chest pain and ST-segment elevation >50% at 90 minutes, abrupt creatine kinase rise before 12 hours, and T-wave inversion in infarct-related electrocardiographic leads within the first 24 hours after thrombolysis.


RESULTS
Global in-hospital mortality rate was 12.0%. Each reperfusion marker was associated with improved outcome. Multivariate logistic regression analysis showed that 3 of the 4 markers of coronary artery reperfusion were significantly and independently associated to low in-hospital mortality rate. The presence of early T-wave inversion was associated with the lowest in-hospital mortality rate (odds ratio 0.25, confidence interval 0. 10-0.56). When all markers of coronary artery reperfusion were included in the regression model, T-wave inversion (odds ratio 0.29, confidence interval 0.11-0.68) and abrupt creatine kinase rise (odds ratio 0.36, confidence interval 0.16-0.77) continued to be significantly associated with better outcome.


CONCLUSIONS
A systemic analysis of noninvasive markers of coronary artery reperfusion can provide the clinician with an excellent tool to predict clinical outcomes when treating myocardial infarction.
Corbalán
R
R
GEMI Group, Santiago, Chile.
Prieto
J C
JC
Chavez
E
E
Nazzal
C
C
Cumsille
F
F
Krucoff
M
M
D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D015425:Myocardial Reperfusion; D017063:Outcome Assessment, Health Care; D019095:Point-of-Care Systems; D011237:Predictive Value of Tests; D011379:Prognosis; D012680:Sensitivity and Specificity; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D014654:Vascular Patency
D005343:Fibrinolytic Agents; D013300:Streptokinase